Cardiovascular Industry($EW, $SNY, $BMY...) Stocks: A Closer Look at the 7.19% Average Gain in the Last Mont
The cardiovascular sector is a dynamic blend of medical device manufacturers, pharmaceutical giants, and biotech innovators. Companies like Boston Scientific are at the forefront of medical device innovation, producing stents that ensure unobstructed blood flow through arteries and valves. On the pharmaceutical front, industry leaders like Sanofi, Bristol Myers Squibb, and Amarin are dedicated to the development and production of drugs that combat cardiovascular diseases. These companies collectively represent a significant portion of the healthcare sector, with a shared mission: to prevent, treat, and cure cardiovascular ailments. Their positioning within the healthcare sector offers them a unique advantage, making them less reliant on the broader economy's fluctuations. This is because the healthcare sector, by its very nature, remains somewhat defensive; after all, medical treatments and medications remain essential, irrespective of economic conditions.
Tickers in Industry - $EW, $SNY, $BMY, $BSX, $CRMD, $ATXS, $CAPR, $ARDX, $MDGL
Swing Trader for Beginners: Trading in Markets Trending Down (TA&FA) - Annualized Return + 64%
Notable Companies
- Bristol-Myers Squibb Co (NYSE:BMY)
- Boston Scientific Corp (NYSE:BSX)
- Edwards Lifesciences Corp (NYSE:EW)
- Amarin Corp (NASDAQ:AMRN)
Market Capitalization The cardiovascular sector boasts an average market capitalization of $32.8B. Valuations within this group vary widely, from a mere $15K to a staggering $134B. Sanofi (SNY) emerges as the group's most valued entity at $134B, while PHASQ stands at the opposite end of the spectrum with a valuation of just $15K.
Price Movements: Highs and Lows Over the past week, stocks within the cardiovascular sector have seen an average growth of 2.8%. This momentum extends to the monthly timeframe, with an impressive average growth of 3.27%. However, the quarterly growth paints a different picture, registering a decline of -10.03%. Ardelyx (ARDX) outperformed its peers with a remarkable price growth of 22.34%. Conversely, CAPR faced the steepest decline at -14.93%.
Key Price Movements:
- Boston Scientific (BSX, $53.79) recorded a significant weekly gain of +6.68% as of 8/29/23.
- Ardelyx (ARDX, $3.72) faced a weekly decline of -6.06% as of 8/17/23.
- Bristol-Myers Squibb (BMY, $61.41) also saw a weekly decline, dropping by -5.06% as of 7/29/23.
Volume Analysis The cardiovascular sector experienced an average weekly volume decline of -0.47%. This trend continued into the monthly and quarterly timeframes, with declines of -21.92% and -59.59% respectively.
Noteworthy Volume Movements:
- Ardelyx stock witnessed a record-breaking daily growth of 278% of the 65-Day Volume Moving Average on 6/24/23.
- Astria Therapeutics stock saw an astounding daily growth of 1,377% of the 65-Day Volume Moving Average on 6/24/23.
- Another notable volume spike for Astria Therapeutics was recorded on 6/3/23, with a daily growth of 342% of the 65-Day Volume Moving Average.
Fundamental Analysis Ratings The cardiovascular sector's fundamental analysis ratings provide insights into the industry's health and potential. While specific ratings were not provided, it's essential to note that a rating closer to 1 indicates a more favorable outlook, while a rating closer to 100 suggests challenges or concerns.
The cardiovascular sector's recent performance, particularly the 7.19% average monthly gain, underscores its resilience and potential for growth. As medical advancements continue and the demand for cardiovascular treatments rises, this sector remains one to watch closely.
EW - On September 1, 2023, the Aroon Indicator for EW showcased a bearish trend. Tickeron's A.I.dvisor detected a scenario where the AroonDown line surpassed 70, while the AroonUp line remained under 30 for three consecutive days. Historically, such a pattern often precedes a notable decline in the stock. Investors might contemplate offloading their shares or exploring put options. Out of 99 past occurrences of this pattern, 67 times the stock trended downwards, translating to a 68% probability of a similar outcome this time.
SNY - On August 2, 2023, SNY breached its lower Bollinger Band, hinting at a potential upward price trajectory. Historically, such a move often leads to the stock rebounding towards the middle band. Investors might see this as an opportune moment to acquire shares or delve into call options. Past data reveals that in 22 out of 33 instances where SNY surpassed its lower Bollinger Band, the stock experienced a price hike in the subsequent month. This suggests a 67% likelihood of an upward continuation.
BMY - On August 29, 2023, BMY surpassed its upper Bollinger Band, potentially signaling a forthcoming price decline as it might revert below the upper band, aiming for the middle band. Investors should contemplate offloading their holdings or investigating put options. Historical analysis by the A.I.dvisor reveals that in 21 out of 36 cases where BMY exceeded its upper Bollinger Band, the stock experienced a subsequent drop. This indicates a 58% probability of a downward trend.
EW's Indicator enters downward trend
The Aroon Indicator for EW entered a downward trend on September 28, 2023. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 109 similar instances where the Aroon Indicator formed such a pattern. In of the 109 cases the stock moved lower. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 08, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on EW as a result. In of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for EW turned negative on September 21, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EW declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
EW may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EW’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.671) is normal, around the industry mean (24.903). P/E Ratio (30.960) is within average values for comparable stocks, (79.136). Projected Growth (PEG Ratio) (4.115) is also within normal values, averaging (6.212). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (7.610) is also within normal values, averaging (58.113).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
General Information
a manufacturer of products to treat late-stage cardiovascular disease
Industry MedicalSpecialties
EW and
Correlation & Price change
A.I.dvisor indicates that over the last year, EW has been loosely correlated with LMAT. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if EW jumps, then LMAT could also see price increases.